Search

Search Constraints

Start Over You searched for: Authors Pearson, Steven D., author Remove constraint Authors: Pearson, Steven D., author

Search Results

5. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: comparative clinical effectiveness and value : evidence report

8. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

10. Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report

14. Palliative care in the outpatient setting: a comparative effectiveness report : final report

16. Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value

17. Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary

18. Supervised injection facilities and other supervised consumption sites: effectiveness and value : final report

19. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report

21. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

22. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

23. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value : final evidence report

26. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report

27. Lecanemab for early Alzheimer’s disease: final evidence report

28. Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report

29. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report

30. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report

31. Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report

32. Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report

35. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value : final report

37. Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value : final report

40. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value : final evidence report and meeting summary

41. Oral immunotherapy and Viaskin Peanut for peanut allergy: effectiveness and value : final evidence report

42. Targeted immune modulators for ulcerative colitis: effectiveness and value : final evidence report and meeting summary

43. AMX0035 and oral edaravone for amyotrophic lateral sclerosis: final evidence report

44. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report

45. Betibeglogene autotemcel for beta thalassemia: effectiveness and value : final evidence report

46. Special assessment of outpatient treatments for COVID-19: final evidence report and meeting summary

47. Medications for obesity management: effectiveness and value : final evidence report

48. Tirzepatide for type 2 diabetes: final report